Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Logility DemandAI+ is now on Aptean AppCentral—bringing agentic AI to demand planning with prebuilt agents for faster, more accurate forecasts.
-
WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary...
-
FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer Updated CRB-701...
-
SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen...
-
WEST HOLLYWOOD, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- VisionWave Holdings, Inc. (Nasdaq: VWAV) ("VisionWave" or the "Company"), a dual-market autonomous systems platform company developing...
-
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
-
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
-
Q4 Revenue Increased 288% Year-over-Year; Full-Year Revenue Increased 627%, with Gross Margin Expanding from 40.3% to 50.1% Significant End-Customer Wins Across Premium Casual Dining, Food Retail,...
-
BERKELEY, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Deep Isolation Nuclear, Inc. (“Deep Isolation” or the “Company”), a leading innovator in nuclear waste disposal technology, today announced that...
-
Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026The trial has already yielded encouraging one- and two-year data...